Difference between revisions of "Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5 (Q9850)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 137, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago...) |
||
Property / title | |||
+ | A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English) | ||
Property / title: A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English) / rank | |||
+ | Normal rank |
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Diaz-Padilla I
0 references
2015
0 references
Gynecol. Oncol.
0 references
137
0 references
A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English)
0 references